With the FDA designate in hand, XCath will further the development of its system that is intended to broaden access to stroke treatment globally.
UCI Health, the clinical enterprise of the University of California, Irvine, is conducting a first-in-human, Phase I clinical trial using laser light to target localized but inoperable pancreatic tumors to help patients become cancer-free.
Adelaide University researchers have developed a new way to use mRNA technology to reprogram tumor-supporting immune cells and strengthen the body’s anticancer immune response.
Columbia University researchers have identified a way to help predict when people at high risk of developing Alzheimer’s are likely to develop their first symptoms, a finding that could help physicians decide when to prescribe preventive treatments currently in development.
The FDA’s decision follows a clinical assessment of the Emboliner, including the PROTECT H2H IDE study.
A family of nanoparticles—tiny, biodegradable molecules commonly used to deliver drugs to patients—shows promise in treating Alzheimer’s disease without additional medication, according to new research from a University of Alberta neuroscientist.
CAR T cell therapy, which involves genetically modifying a patient’s own immune cells to fight cancer, is a technique that has shown great promise, especially against blood cancers. But currently, only about 4% of patients with advanced or metastatic cancer in the United States are candidates for CAR T therapy, and closer to 3% will actually benefit, according to one recent analysis.
A new report in the New England Journal of Medicine by researchers at Baylor College of Medicine, Texas Children’s Hospital and Seattle Children’s describes a complete regression of hepatoblastoma, the most common pediatric liver cancer, in a 3-year-old treated with a novel immunotherapy.
LONDON, Sept. 9, 2026 /PRNewswire/ — Full-Life Technologies (“Full-Life”, the “Company”), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for [225Ac]Ac-FL-261 and that the program has received Australian Human Research Ethics Committee (“HREC”) approval and completed the Clinical Trial Notification (“CTN”) process with Therapeutic Goods Administration (“TGA”).
WashU Medicine researchers led by Jacco Boon, a professor in the John T. Milliken Department of Medicine, report that an experimental bird flu vaccine provides strong immune protection in mice, including in animals previously vaccinated against seasonal flu. Because pre-existing immunity from prior seasonal influenza infection or vaccination could diminish the efficacy of H5N1 vaccines, showing that the new vaccine succeeds alongside existing immunity is a crucial milestone.